Global Protein Biochips Market Overview:
Over the past few decades, the development of protein biochips is in progress significantly and has been achieved in terms of increasing sensitivity of detection. Protein Biochips, an emerging class of proteomic technologies, systems that automate protein identification, quantification, and studies of biomolecular interactions and it is the logical extension of the DNA biochip. It is categorized into the two classes of protein biochips are currently available analytical and functional protein microarrays. Analytical class is frequently antibody microarrays, have become one of the most important multiplexed detection technologies and Functional class are being frequently applied to various areas of biological process, including studies of protein interaction, biochemical activity and others. The demand for protein biochips is increasing in the market as it is being applied in any area of biological discovery, including the studies of protein interactions, biochemical activity and immune responses and others.
- The growing use of the Protein biochips in personalized medicine
- High demand for protein biochips over the antibody sandwich microarrays
- The use of protein biochips in cancer in personalized medicine is based on this type of human pathology is trending
- The trend of customization protein biochips
- High cost associated with the Protein microchips
- High demand for Protein biochips in oncology
- Increasing the use of protein microarrays for allergy screening and vaccine development
- Management of the Complexity by dividing and conquering the proteome
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Agilent Technologies, Inc. (United States), SEPMAG Technologies (Spain), BD Biosciences (United States), Merck KGaA (Germany), Beckman Coulter, Inc. (United States), Alfa Wassermann Inc. (United States), Repligen Corporation (United States), ProMetic Life Sciences, Inc. (Canada), Thermo Fisher Scientific, Inc. (United States), Shimadzu Scientific Instruments (United States) and Groupe Novasep (France). Additionally, following companies can also be profiled that are part of our coverage like Becton, Dickinson and Company (United States), Bio-Rad Laboratories, Inc. (United States), Atoll GmbH (Germany) and Affymetrix, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Protein Biochips market by 2026. Considering Market by Protein Detection method, the sub-segment i.e. Label dependent will boost the Protein Biochips market. Considering Market by End User, the sub-segment i.e. Biotechnology and Pharmaceutical Companies will boost the Protein Biochips market. Considering Market by Technologies, the sub-segment i.e. Robotic printer will boost the Protein Biochips market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Protein Biochips market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Protein Biochips market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Protein Biochips Manufacturer, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.